Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$376.07 USD

376.07
435,083

+1.13 (0.30%)

Updated Aug 7, 2025 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic Gets Expanded FDA Nod for MiniMed 670G System

by Zacks Equity Research

Medtronic (MDT) continues to adopt initiatives to bolster the Diabetes segment.

    Zacks Equity Research

    Here's Why You Should Hold Merit Medical (MMSI) Stock Now

    by Zacks Equity Research

    Here we take a quick look at the major factors that plague Merit Medical (MMSI) and discuss the prospects that ensure near-term recovery.

      Zacks Equity Research

      Here's Why You Should Buy Integra LifeSciences (IART) Stock

      by Zacks Equity Research

      Integra LifeSciences' (IART) key developments on the overseas front buoy optimism on the stock among investors.

        Zacks Equity Research

        Accuray's Radixact Gets AERB Nod in India, Prospects Solid

        by Zacks Equity Research

        The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.

          Zacks Equity Research

          Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now

          by Zacks Equity Research

          Here we discuss the primary factors that are plaguing AmerisourceBergen (ABC) and the prospects that indicate near-term recovery.

            Zacks Equity Research

            Patterson Companies' (PDCO) Earnings Meet Estimates in Q4

            by Zacks Equity Research

            Lackluster sales and earnings performance dampened Patterson Companies' (PDCO) fourth-quarter results.

              Zacks Equity Research

              Is Stryker (SYK) Outperforming Other Medical Stocks This Year?

              by Zacks Equity Research

              Is Stryker Corporation (SYK) Outperforming Other Medical Stocks This Year?

                Zacks Equity Research

                Here's Why You Should Steer Clear of Cerner (CERN) for Now

                by Zacks Equity Research

                Cerner's (CERN) downbeat view for 2018 and soft segmental performances fail to cheer investors.

                  Zacks Equity Research

                  Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring

                  by Zacks Equity Research

                  Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.

                    Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Schlumberger, Walgreens Boots, BNY Mellon, Stryker and Duke Energy

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Schlumberger, Walgreens Boots, BNY Mellon, Stryker and Duke Energy

                      Zacks Equity Research

                      Here's Why You Should Hold Onto DENTSPLY SIRONA Stock Now

                      by Zacks Equity Research

                      DENTSPLY SIRONA (XRAY) gains from its increasing focus on innovation while a lowered earnings guidance for 2018 raises concern.

                        Zacks Equity Research

                        Varian Medical's (VAR) ProBeam Platform Gains Foothold in UK

                        by Zacks Equity Research

                        Varian Medical's (VAR) ProBeam system is the first of its kind to deliver intensity-modulated proton therapy.

                          Nabaparna Bhattacharya headshot

                          Mechatronics for Healthcare: 3 MedTech Stocks to Bet On

                          by Nabaparna Bhattacharya

                          Here we analyze how Medical Mechatronics is creating new opportunities in MedTech for investors who are keen on putting their money in the healthcare space for longer-term gains.

                            Mark Vickery headshot

                            Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon

                            by Mark Vickery

                            Today's Research Daily features new research reports on 16 major stocks, including Schlumberger (SLB), Walgreens Boots (WBA) and BNY Mellon (BK).

                              Zacks Equity Research

                              Haemonetics' Plasma Momentum Solid, Margins Gain Traction

                              by Zacks Equity Research

                              Solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth for Haemonetics (HAE).

                                Zacks Equity Research

                                ResMed Inks Deal With athenaHealth on Brightree's eReferral

                                by Zacks Equity Research

                                ResMed's (RMD) wholly owned unit Brightree remains integral to the company's group for two full years with a consistent stretch of success.

                                  Zacks Equity Research

                                  Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

                                  by Zacks Equity Research

                                  Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

                                    Zacks Equity Research

                                    Here's Why You Should Steer Clear of Express Scripts for Now

                                    by Zacks Equity Research

                                    Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.

                                      Zacks Equity Research

                                      Cardinal Health (CAH), CD&R to Jointly Invest in naviHealth

                                      by Zacks Equity Research

                                      Cardinal Health (CAH) intends to boost its acute-care program platform by jointly investing in the earlier acquired naviHealth along with Clayton, Dubilier & Rice.

                                        Zacks Equity Research

                                        PetMed (PETS) Optimistic About New Orders Amid Cost Woes

                                        by Zacks Equity Research

                                        The whole of fiscal 2018 demonstrates an upbeat momentum for PetMed's (PETS) new order sales, primarily backed by aggressive advertising.

                                          Zacks Equity Research

                                          Medtronic ActivaProgramming Application Wins FDA Nod for DBS

                                          by Zacks Equity Research

                                          Medtronic's (MDT) ActivaProgramming Application is designed for use with Samsung Galaxy Tab S2 tablets. The therapy incorporates the inputs of more than a 100 clinicians worldwide.

                                            Zacks Equity Research

                                            SYK or SRDX: Which is a Better Medical Product Stock?

                                            by Zacks Equity Research

                                            Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.

                                              Zacks Equity Research

                                              Cardinal Health to Gain From FDA Panel Vote for INCRAFT PMA

                                              by Zacks Equity Research

                                              Cardinal Health's (CAH) INCRAFT receives favorable recommendation from FDA for premarket approval.

                                                Zacks Equity Research

                                                Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?

                                                by Zacks Equity Research

                                                Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.

                                                  Zacks Equity Research

                                                  Zacks.com highlights: Buckle, MasTec, ShotSpotter, Old Dominion Freight Line and Stryker

                                                  by Zacks Equity Research

                                                  Zacks.com highlights: Buckle, MasTec, ShotSpotter, Old Dominion Freight Line and Stryker